Review





Similar Products

limpii scarb2 human gene knockout kit human gene knockout kit crispr  (OriGene)
94
OriGene limpii scarb2 human gene knockout kit human gene knockout kit crispr
LYSOTAC partially recovers GCase activity in LIMP-2 deficient HEK293 cells. (A) Scheme of generating <t>SCARB2</t> -/- clones (Created in BioRender. Park, J. (2026) https://BioRender.com/6qf7ykt ); (B) WB of HEK293 cell clones transfected with gRNA vector targeting SCARB2 ; Relative quantification of (C) LIMP-2 and (D) GCase compared to control HEK293 cells in (B) ( n = 5); (E) GCase activity of HEK293 cell clones transfected with gRNA vector targeting SCARB2 ( n = 5); GCase activity of LIMP-2 deficient HEK293 cells (clone #2) exposed to (F) ATB2057 or (G) ATB2058 for 7 d was compared with control HEK293 cells ( n = 5); (H, I) Increased GCase activity of LIMP-2 deficient HEK293 cells in (F) and (G) is shown as a percentage change ( n = 5); (J) GCase activity of LIMP-2 deficient HEK293 cells treated with ATB2057 (1 µM), ATB1021 (1 µM), JZ-4109 (1 µM), and ambroxol (1 or 50 µM) for 7 d. Differences between groups were evaluated by one-way ANOVA (C, D, E, H, I, and J) or two-way ANOVA (F and G). The data are presented as the mean ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001.
Limpii Scarb2 Human Gene Knockout Kit Human Gene Knockout Kit Crispr, supplied by OriGene, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/limpii/pmc13099342-60-7-17?v=OriGene
Average 94 stars, based on 1 article reviews
limpii scarb2 human gene knockout kit human gene knockout kit crispr - by Bioz Stars, 2026-08
94/100 stars
  Buy from Supplier
limpii  (Proteintech)
93
Proteintech limpii
LYSOTAC partially recovers GCase activity in LIMP-2 deficient HEK293 cells. (A) Scheme of generating <t>SCARB2</t> -/- clones (Created in BioRender. Park, J. (2026) https://BioRender.com/6qf7ykt ); (B) WB of HEK293 cell clones transfected with gRNA vector targeting SCARB2 ; Relative quantification of (C) LIMP-2 and (D) GCase compared to control HEK293 cells in (B) ( n = 5); (E) GCase activity of HEK293 cell clones transfected with gRNA vector targeting SCARB2 ( n = 5); GCase activity of LIMP-2 deficient HEK293 cells (clone #2) exposed to (F) ATB2057 or (G) ATB2058 for 7 d was compared with control HEK293 cells ( n = 5); (H, I) Increased GCase activity of LIMP-2 deficient HEK293 cells in (F) and (G) is shown as a percentage change ( n = 5); (J) GCase activity of LIMP-2 deficient HEK293 cells treated with ATB2057 (1 µM), ATB1021 (1 µM), JZ-4109 (1 µM), and ambroxol (1 or 50 µM) for 7 d. Differences between groups were evaluated by one-way ANOVA (C, D, E, H, I, and J) or two-way ANOVA (F and G). The data are presented as the mean ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001.
Limpii, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/limpii/pmc12779575-261-125-126?v=Proteintech
Average 93 stars, based on 1 article reviews
limpii - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier
nb400 129 ab 2301298 novus biologicals c terminus rabbit polyclonal  (Novus Biologicals)
93
Novus Biologicals nb400 129 ab 2301298 novus biologicals c terminus rabbit polyclonal
LYSOTAC partially recovers GCase activity in LIMP-2 deficient HEK293 cells. (A) Scheme of generating <t>SCARB2</t> -/- clones (Created in BioRender. Park, J. (2026) https://BioRender.com/6qf7ykt ); (B) WB of HEK293 cell clones transfected with gRNA vector targeting SCARB2 ; Relative quantification of (C) LIMP-2 and (D) GCase compared to control HEK293 cells in (B) ( n = 5); (E) GCase activity of HEK293 cell clones transfected with gRNA vector targeting SCARB2 ( n = 5); GCase activity of LIMP-2 deficient HEK293 cells (clone #2) exposed to (F) ATB2057 or (G) ATB2058 for 7 d was compared with control HEK293 cells ( n = 5); (H, I) Increased GCase activity of LIMP-2 deficient HEK293 cells in (F) and (G) is shown as a percentage change ( n = 5); (J) GCase activity of LIMP-2 deficient HEK293 cells treated with ATB2057 (1 µM), ATB1021 (1 µM), JZ-4109 (1 µM), and ambroxol (1 or 50 µM) for 7 d. Differences between groups were evaluated by one-way ANOVA (C, D, E, H, I, and J) or two-way ANOVA (F and G). The data are presented as the mean ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001.
Nb400 129 Ab 2301298 Novus Biologicals C Terminus Rabbit Polyclonal, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/limpii/pmc12577314__13024_2025_884_MOESM1_ESM-40-0-3?v=Novus+Biologicals
Average 93 stars, based on 1 article reviews
nb400 129 ab 2301298 novus biologicals c terminus rabbit polyclonal - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier
limp2  (Proteintech)
93
Proteintech limp2
LYSOTAC partially recovers GCase activity in LIMP-2 deficient HEK293 cells. (A) Scheme of generating <t>SCARB2</t> -/- clones (Created in BioRender. Park, J. (2026) https://BioRender.com/6qf7ykt ); (B) WB of HEK293 cell clones transfected with gRNA vector targeting SCARB2 ; Relative quantification of (C) LIMP-2 and (D) GCase compared to control HEK293 cells in (B) ( n = 5); (E) GCase activity of HEK293 cell clones transfected with gRNA vector targeting SCARB2 ( n = 5); GCase activity of LIMP-2 deficient HEK293 cells (clone #2) exposed to (F) ATB2057 or (G) ATB2058 for 7 d was compared with control HEK293 cells ( n = 5); (H, I) Increased GCase activity of LIMP-2 deficient HEK293 cells in (F) and (G) is shown as a percentage change ( n = 5); (J) GCase activity of LIMP-2 deficient HEK293 cells treated with ATB2057 (1 µM), ATB1021 (1 µM), JZ-4109 (1 µM), and ambroxol (1 or 50 µM) for 7 d. Differences between groups were evaluated by one-way ANOVA (C, D, E, H, I, and J) or two-way ANOVA (F and G). The data are presented as the mean ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001.
Limp2, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/limpii/bio_rxiv__2025__09__04__674289-200-120-130?v=Proteintech
Average 93 stars, based on 1 article reviews
limp2 - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier
rabbit polyclonal anti limp 2 antibody  (Novus Biologicals)
93
Novus Biologicals rabbit polyclonal anti limp 2 antibody
LYSOTAC partially recovers GCase activity in LIMP-2 deficient HEK293 cells. (A) Scheme of generating <t>SCARB2</t> -/- clones (Created in BioRender. Park, J. (2026) https://BioRender.com/6qf7ykt ); (B) WB of HEK293 cell clones transfected with gRNA vector targeting SCARB2 ; Relative quantification of (C) LIMP-2 and (D) GCase compared to control HEK293 cells in (B) ( n = 5); (E) GCase activity of HEK293 cell clones transfected with gRNA vector targeting SCARB2 ( n = 5); GCase activity of LIMP-2 deficient HEK293 cells (clone #2) exposed to (F) ATB2057 or (G) ATB2058 for 7 d was compared with control HEK293 cells ( n = 5); (H, I) Increased GCase activity of LIMP-2 deficient HEK293 cells in (F) and (G) is shown as a percentage change ( n = 5); (J) GCase activity of LIMP-2 deficient HEK293 cells treated with ATB2057 (1 µM), ATB1021 (1 µM), JZ-4109 (1 µM), and ambroxol (1 or 50 µM) for 7 d. Differences between groups were evaluated by one-way ANOVA (C, D, E, H, I, and J) or two-way ANOVA (F and G). The data are presented as the mean ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001.
Rabbit Polyclonal Anti Limp 2 Antibody, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/limpii/pm40639771-143-27-32?v=Novus+Biologicals
Average 93 stars, based on 1 article reviews
rabbit polyclonal anti limp 2 antibody - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier
n a limp2  (Novus Biologicals)
93
Novus Biologicals n a limp2
LYSOTAC partially recovers GCase activity in LIMP-2 deficient HEK293 cells. (A) Scheme of generating <t>SCARB2</t> -/- clones (Created in BioRender. Park, J. (2026) https://BioRender.com/6qf7ykt ); (B) WB of HEK293 cell clones transfected with gRNA vector targeting SCARB2 ; Relative quantification of (C) LIMP-2 and (D) GCase compared to control HEK293 cells in (B) ( n = 5); (E) GCase activity of HEK293 cell clones transfected with gRNA vector targeting SCARB2 ( n = 5); GCase activity of LIMP-2 deficient HEK293 cells (clone #2) exposed to (F) ATB2057 or (G) ATB2058 for 7 d was compared with control HEK293 cells ( n = 5); (H, I) Increased GCase activity of LIMP-2 deficient HEK293 cells in (F) and (G) is shown as a percentage change ( n = 5); (J) GCase activity of LIMP-2 deficient HEK293 cells treated with ATB2057 (1 µM), ATB1021 (1 µM), JZ-4109 (1 µM), and ambroxol (1 or 50 µM) for 7 d. Differences between groups were evaluated by one-way ANOVA (C, D, E, H, I, and J) or two-way ANOVA (F and G). The data are presented as the mean ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001.
N A Limp2, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/limpii/pmc12094229__sciadv%2Eads3393_sm-210-44-47?v=Novus+Biologicals
Average 93 stars, based on 1 article reviews
n a limp2 - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier
human scarb2 fc  (R&D Systems)
93
R&D Systems human scarb2 fc
LYSOTAC partially recovers GCase activity in LIMP-2 deficient HEK293 cells. (A) Scheme of generating <t>SCARB2</t> -/- clones (Created in BioRender. Park, J. (2026) https://BioRender.com/6qf7ykt ); (B) WB of HEK293 cell clones transfected with gRNA vector targeting SCARB2 ; Relative quantification of (C) LIMP-2 and (D) GCase compared to control HEK293 cells in (B) ( n = 5); (E) GCase activity of HEK293 cell clones transfected with gRNA vector targeting SCARB2 ( n = 5); GCase activity of LIMP-2 deficient HEK293 cells (clone #2) exposed to (F) ATB2057 or (G) ATB2058 for 7 d was compared with control HEK293 cells ( n = 5); (H, I) Increased GCase activity of LIMP-2 deficient HEK293 cells in (F) and (G) is shown as a percentage change ( n = 5); (J) GCase activity of LIMP-2 deficient HEK293 cells treated with ATB2057 (1 µM), ATB1021 (1 µM), JZ-4109 (1 µM), and ambroxol (1 or 50 µM) for 7 d. Differences between groups were evaluated by one-way ANOVA (C, D, E, H, I, and J) or two-way ANOVA (F and G). The data are presented as the mean ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001.
Human Scarb2 Fc, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/limpii/pmc12178775-95-19-21?v=R%26D+Systems
Average 93 stars, based on 1 article reviews
human scarb2 fc - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier

Image Search Results


LYSOTAC partially recovers GCase activity in LIMP-2 deficient HEK293 cells. (A) Scheme of generating SCARB2 -/- clones (Created in BioRender. Park, J. (2026) https://BioRender.com/6qf7ykt ); (B) WB of HEK293 cell clones transfected with gRNA vector targeting SCARB2 ; Relative quantification of (C) LIMP-2 and (D) GCase compared to control HEK293 cells in (B) ( n = 5); (E) GCase activity of HEK293 cell clones transfected with gRNA vector targeting SCARB2 ( n = 5); GCase activity of LIMP-2 deficient HEK293 cells (clone #2) exposed to (F) ATB2057 or (G) ATB2058 for 7 d was compared with control HEK293 cells ( n = 5); (H, I) Increased GCase activity of LIMP-2 deficient HEK293 cells in (F) and (G) is shown as a percentage change ( n = 5); (J) GCase activity of LIMP-2 deficient HEK293 cells treated with ATB2057 (1 µM), ATB1021 (1 µM), JZ-4109 (1 µM), and ambroxol (1 or 50 µM) for 7 d. Differences between groups were evaluated by one-way ANOVA (C, D, E, H, I, and J) or two-way ANOVA (F and G). The data are presented as the mean ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001.

Journal: Asian Journal of Pharmaceutical Sciences

Article Title: Targeted delivery of glucocerebrosidase to lysosomes: The LYSOTAC (LYSOsome-TArgeting Chimera) technology

doi: 10.1016/j.ajps.2026.101149

Figure Lengend Snippet: LYSOTAC partially recovers GCase activity in LIMP-2 deficient HEK293 cells. (A) Scheme of generating SCARB2 -/- clones (Created in BioRender. Park, J. (2026) https://BioRender.com/6qf7ykt ); (B) WB of HEK293 cell clones transfected with gRNA vector targeting SCARB2 ; Relative quantification of (C) LIMP-2 and (D) GCase compared to control HEK293 cells in (B) ( n = 5); (E) GCase activity of HEK293 cell clones transfected with gRNA vector targeting SCARB2 ( n = 5); GCase activity of LIMP-2 deficient HEK293 cells (clone #2) exposed to (F) ATB2057 or (G) ATB2058 for 7 d was compared with control HEK293 cells ( n = 5); (H, I) Increased GCase activity of LIMP-2 deficient HEK293 cells in (F) and (G) is shown as a percentage change ( n = 5); (J) GCase activity of LIMP-2 deficient HEK293 cells treated with ATB2057 (1 µM), ATB1021 (1 µM), JZ-4109 (1 µM), and ambroxol (1 or 50 µM) for 7 d. Differences between groups were evaluated by one-way ANOVA (C, D, E, H, I, and J) or two-way ANOVA (F and G). The data are presented as the mean ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001.

Article Snippet: LIMP-2-deficient HEK293 cells were produced using a LIMPII (SCARB2) Human Gene Knockout Kit (CRISPR) (# KN402162 ; Origene, Rockville, MD, USA) according to the manufacturer’s instructions.

Techniques: Activity Assay, Clone Assay, Transfection, Plasmid Preparation, Quantitative Proteomics, Control